Therapeutic effect of nenoxacin on patients with adult community acquired pneumonia / 中国中西医结合急救杂志

ABSTRACT

Objective To evaluate the efficacy and safety of nemonoxacin as a combination drug in the treatment of patients with adult community acquired pneumonia (CAP) in the Department of Respiratory. Methods The data of patients with CAP treated with nemonoxacin as an agent in a combined therapy and admitted to Department of Respiratory of Shengjing Hospital of China Medical University from July to October 2018 were retrospectively analyzed. The patients' symptoms, curative effects and adverse reactions were recorded. Results Totally 48 patients with CAP were treated with combined nemonoxacin, including 6 patients with severe pneumonia. All the patients were treated with intravenous drip of β-lactams combined with oral nemonoxacin 500 mg, once a day. After 3 days of treatment, the improvement rate of symptoms was 47.92% (23/48), and 89.58% (43/48) of the patients were cured or improved after (9.83±3.49) days of treatment, no adverse reactions occurred during the period of oral administration;91.67% (44/48) of the patients were satisfied with the effect of medication. Compared with 178 CAP patients who were hospitalized in Department of Respiratory in the same period in 2017, the patients' length of stay in hospital in the present study was shorter (days 12.52±4.45 vs. 14.53±6.73, P < 0.05). Conclusion As a combination drug, nemonoxacin is a safe and effective treatment for CAP patients admitted to Department of Respiratory, it can better control symptoms, shorten hospitalization time, induce less adverse reactions and its patients' tolerance is good.